Giovanni Caforio’s stock holdings at Bristol-Myers Squibb have seen some significant fluctuations between 2020 and 2023. His wealth peaked at approximately $13 million in stock holdings back in 2020, largely due to performance-based awards that vested while his company thrived....

Giovanni Caforio’s stock holdings at Bristol-Myers Squibb have seen some significant fluctuations between 2020 and 2023. His wealth peaked at approximately $13 million in stock holdings back in 2020, largely due to performance-based awards that vested while his company thrived. However, by 2023, Caforio had no new grants or options, indicating a strategic shift as he prepared to pass leadership to a successor. His commitment to long-term value creation is reflected in these holdings as he has consistently maintained a stake that aligns with Bristol-Myers' growth. This highlights his confidence in the company's direction even as he plans to transition away from the chief executive position.